ArticleBiology direct2026
Solute carrier family (SLC) amino acid transporters are upregulated in cutaneous squamous cell carcinoma.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Solute carrier family (SLC) amino acid transporters play key role in maintaining a continuous supply of nutrients to cancer cells. Non melanoma skin tumours, the most common cancer type worldwide, undergo extensive metabolic rewiring to survive under hostile conditions. To adapt to nutrient-poor microenvironment, tumour cells often boost expression of the key metabolic enzymes. However, the role of the amino acid transporters and their therapeutic potential in non-melanoma skin cancer remain unclear. Here, we analyse publicly available transcriptomics data and identify several amino acid transporters that are strongly upregulated in skin cancer, including neutral amino acid transporter LAT1. LAT1 is overexpressed in proliferating basal-like cells within skin tumours and its level decreases during epidermal differentiation. Furthermore, we show that cutaneous squamous cell carcinoma cells rely on citrulline to survive under arginine scarcity and LAT1 is essential for citrulline import. Pharmacological inhibition of LAT1 by the small compound JPH203 sensitises cells to arginine deprivation. Altogether, we show that amino transporter LAT1 plays an important role in cutaneous squamous cell carcinoma growth in low arginine conditions and highlight its potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.